{"filing":{"accession_number":"0001171843-26-005575","cik":"0001628808","ticker":"PROF","company_name":"Profound Medical Corp.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-14","primary_document":"f8k_081726.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326005575/f8k_081726.htm"},"events":[{"id":28066,"run_id":25650,"accession_number":"0001171843-26-005575","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.9,"summary":"Matthew Sobczyk was promoted from Corporate Controller to Interim Chief Financial Officer effective August 14, 2026, succeeding Rashed Dewan who resigned from the CFO position. The appointment addresses the company's financial leadership continuity following the departure of the prior CFO.","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29864,"accession_number":"0001171843-26-005575","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two principal executive events: the resignation of Rashed Dewan as CFO and the appointment of Matthew Sobczyk as Interim CFO, both effective August 14, 2026. While both a departure and appointment occur, the central narrative and press release emphasize Sobczyk's promotion and appointment (\"promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately\"), making the appointment the salient event. The appointment of an interim CFO is material to investors as it affects the company's financial leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:55:46.377139+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29865,"accession_number":"0001171843-26-005575","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately, succeeding Rashed Dewan who has stepped down. While this Item 7.01 is a Regulation FD disclosure of a press release, the substantive event is an executive appointment to a named officer role (CFO), which is material to investors assessing company leadership and continuity. The appointment of an interim CFO following the departure of the prior CFO is a significant governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:55:46.377139+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29864,"accession_number":"0001171843-26-005575","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two principal executive events: the resignation of Rashed Dewan as CFO and the appointment of Matthew Sobczyk as Interim CFO, both effective August 14, 2026. While both a departure and appointment occur, the central narrative and press release emphasize Sobczyk's promotion and appointment (\"promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately\"), making the appointment the salient event. The appointment of an interim CFO is material to investors as it affects the company's financial leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:55:46.377139+00:00","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-08-17"},{"id":29865,"accession_number":"0001171843-26-005575","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately, succeeding Rashed Dewan who has stepped down. While this Item 7.01 is a Regulation FD disclosure of a press release, the substantive event is an executive appointment to a named officer role (CFO), which is material to investors assessing company leadership and continuity. The appointment of an interim CFO following the departure of the prior CFO is a significant governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:55:46.377139+00:00","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-08-17"}]}